Data from Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

• DOI: 10.1158/1078-0432.c.7122875.v1
• Publication Date: 2024-03-15T07:21:22Z
• Authors: Joao Paulo Solar ...; Nan Chen; Emma Titmuss; Dongsheng Tu; Stephanie Y. Brule; Rachel Goodwin; Derek J. Jonker; Timothy Price; John R. Zalcberg; Malcolm J. Moore; Christos S. Karap...; Lillian Siu; Jeremy Shapiro; John Simes; Sharlene Gill; Chris J. O'Callaghan; Jonathan M. Loree

<div>AbstractPurpose:<p>Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses sidedness the optimal division between left- right-sided unclear. We investigated transverse primary tumor location as a biomarker mCRC.</p>Experimental Design:<p>Pooled analysis CCTG/AGITG CO.17 CO.20 trials cetuximab chemotherapy-refractory mCRC. Outcomes patients with <i>RAS/BRAF</i> wild-type (WT) mCRC <i>KRAS</i> WT were analyzed according to location.</p>Results:<p>A total 553 analyzed, 32 (5.8%) cancers transverse, 101 (18.3%) right, 420 (75.9%) left colon. failed reach significant benefit versus best supportive care (BSC) for overall survival [OS; median, 5.9 vs. 2.1 months; HR, 0.63; 95% confidence interval (CI), 0.28–1.42; <i>P</i>=0.26] progression-free (PFS; 1.8 1.3 0.57; CI, 0.26–1.28; <i>P</i>=0.16). Analyzing exclusively randomized cetuximab, had comparable outcomes OS (median, 5.6 0.82; 0.50–1.34; <i>P</i>=0.43) PFS 1.9 0.78; 0.49–1.26; <i>P</i>=0.31). Patients left-sided superior compared 9.7 0.42; 0.27–0.67; <i>P</i>=0.0002) 3.8 0,49; 0.31–0.76; <i>P</i>=0.001). Location was not treated BSC alone.</p>Conclusions:<p>Transverse features mCRC.</p></div>